Shopping Cart
- Remove All
Your shopping cart is currently empty
Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1/PD-L1 pathway, serving as a checkpoint inhibitor. It is applicable in research on metastatic cancer and squamous cell skin cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $163 | In Stock | |
| 5 mg | $497 | In Stock | |
| 10 mg | $797 | In Stock |
| Description | Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1/PD-L1 pathway, serving as a checkpoint inhibitor. It is applicable in research on metastatic cancer and squamous cell skin cancer. |
| In vivo | In a mouse model with MC38.Ova tumors, Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) increased the proportion of effector T cells in tumors and dLNs, resulting in reduced tumor growth when combined with immunotherapy using REGN3767[2]. |
| Synonyms | SAR-439684, REGN-2810 |
| Molecular Weight | 143.81 kDa |
| Cas No. | 1801342-60-8 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.